Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2025

Original Article

SGLT2 inhibitors and ovarian cancer risk in women with type 2 diabetes

Impact of sodium-glucose cotransporter-2 inhibitors on ovarian cancer risk in patients with type 2 diabetes mellitus: A multi-institutional TriNetX study.

Diabetes research and clinical practice

Citation & Authors

Diabetes Res Clin Pract. 2025;222:112109.

Cheng-Hsien Hung; Jheng-Yan Wu; Yueh-Shan Weng; Li-Wei Hsiao; Yu-Chang Liu; I-Tsang Chiang

ABSTRACT · RESEARCH SUMMARY

Research summary

Using a new-user, active-comparator design, the TriNetX study matched 92,090 pairs of SGLT2 and DPP-4 inhibitor users. SGLT2 inhibitors were associated with a lower risk of ovarian cancer (HR 0.758; 95% CI 0.596–0.965), with a more pronounced association in the White subgroup. Biological mechanisms and residual confounding require further investigation; this finding is not definitive evidence of cancer prevention.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗